Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.
J Clin Oncol · 2025-Jul · PMID 40215429
OS
FIG 2. OS of sotorasib-panitumumab versus investigator's choice. (A) Kaplan-Meier curves of OS for sotorasib 960 mg-panitumumab (full analysis set). (B) Kaplan-Meier curves of OS for sotorasib 240 mg-panitumumab (full analysis set). (C) Forest plot of sotorasib 960 mg-panitumumab treatment effect on OS in subgroup analyses. (D) Forest plot of sotorasib 240 mg-panitumumab treatment effect on OS in subgroup analyses. The dashed horizontal gray line indicates the median value. Vertical bars indicate censoring. Stratified Cox hazard ratio and stratified log-rank P value for sotorasib-panitumumab versus investigator's choice are provided. The intention-to-treat population included all patients who underwent random assignment. Hazard ratio was not estimated when there were fewer than 10 patients in either treatment arm in a subgroup. HR, hazard ratio; NE, not estimable; OS, overall survival.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-23T17:42:11+00:00 |